Literature DB >> 11557654

Dissolution of calcium pyrophosphate crystals by polyphosphates: an in vitro and ex vivo study.

R Cini1, D Chindamo, M Catenaccio, S Lorenzini, E Selvi, F Nerucci, M P Picchi, G Berti, R Marcolongo.   

Abstract

OBJECTIVE: To determine the dissolving ability (DA) of linear pentasodium tripolyphosphate (PSTP), cyclic trisodium metaphosphate (TSMP), polymeric sodium metaphosphate (SMP) on synthetic crystals of calcium pyrophosphate dihydrate (CPPD) and on crystalline aggregates of menisci from patients with chondrocalcinosis (CC).
METHODS: Synthetic CPPD crystals were mixed with phosphate buffered saline (PBS), which contained the different polyphosphates, for one hour at 37 degrees C. The calcified menisci were obtained from the knees of four female patients with CPPD disease who underwent total arthroscopic meniscectomy for degenerative meniscal lesions. Meniscal cryosections and fragments were incubated in SMP (15 mg/ml PBS) at 37 degrees C for one hour and 24 hours, respectively. Histological evaluation on meniscal samples after polyphosphate incubation was carried out by ordinary transmitted light microscopy and polarised light microscopy. The dissolution of CPPD crystals by polyphosphates was assessed by atomic absorption spectroscopy, which determined the amount of calcium liberated from synthetic crystals and meniscal fragments. Cytotoxicity of SMP was evaluated by tetrazolium salt assay and by an ultrastructural study on cultured chondrocytes.
RESULTS: SMP and PSTP showed higher DA on CPPD crystals than TSMP. Analysis of the DA values at increasing concentrations of SMP showed that a concentration of 15 mg/ml completely dissolved 2.0 mg CPPD crystals. The solution of meniscal CPPD crystals showed a significant increase of calcium concentration after three hours and 24 hours of SMP incubation (p=0.0001; Kruskal-Wallis analysis of variance) compared with fragments incubated in PBS control solution. Macroscopic and microscopic evaluation of meniscal specimens showed a notable reduction of CPPD deposits. A 50% inhibitory dose on cultured chondrocytes was reached at the maximum concentration of SMP used in this work (15 mg/ml); ultrastructural analysis did not show morphological alterations in the treated cells.
CONCLUSION: The results of this study indicate that linear polyphosphates are effective in dissolving both synthetic and ex vivo CPPD crystal aggregates. This suggests a potential therapeutic use for these molecules in the treatment of symptomatic CC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557654      PMCID: PMC1753396          DOI: 10.1136/ard.60.10.962

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Density functional geometry optimization and energy calculations of calcium(II)-triphosphate complexes. Polyphosphates as possible dissolving agents for calcium pyrophosphate dihydrate crystals in chondrocalcinosis disease.

Authors:  R Cini; D Chindamo; M Catenaccio; S Lorenzini; R Marcolongo
Journal:  J Biomol Struct Dyn       Date:  2000-08

2.  Crystal shedding and acute pseudogout. An hypothesis based on a therapeutic failure.

Authors:  R M Bennett; J R Lehr; D J McCarty
Journal:  Arthritis Rheum       Date:  1976 Jan-Feb

3.  Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.

Authors:  J A Plumb; R Milroy; S B Kaye
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

4.  Inhibition of aortic calcification by means of pyrophosphate and polyphosphates.

Authors:  H Fleisch; D Schibler; J Maerki; I Frossard
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

5.  Molecular orbital study of complexes of zinc(II) with sulphide, thiomethanolate, thiomethanol, dimethylthioether, thiophenolate, formiate, acetate, carbonate, hydrogen carbonate, iminomethane and imidazole. Relationships with structural and catalytic zinc in some metallo-enzymes.

Authors:  R Cini
Journal:  J Biomol Struct Dyn       Date:  1999-06

6.  Alkaline phosphatase dissolves calcium pyrophosphate dihydrate crystals.

Authors:  Y Xu; T F Cruz; K P Pritzker
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

7.  Experimental inflammation induced by naturally occurring microcrystalline calcium salts.

Authors:  C W Denko; M W Whitehouse
Journal:  J Rheumatol       Date:  1976-03       Impact factor: 4.666

8.  Effects of pyrophosphatase on dissolution of calcium pyrophosphate dihydrate crystals.

Authors:  Y Xu; T Cruz; P T Cheng; K P Pritzker
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

9.  Crystal-induced neutrophil activation. II. Evidence for the activation of a phosphatidylcholine-specific phospholipase D.

Authors:  P H Naccache; S Bourgoin; E Plante; C J Roberge; R de Medicis; A Lussier; P E Poubelle
Journal:  Arthritis Rheum       Date:  1993-01

10.  The metabolic properties of acid soluble polyphosphates in Saccharomyces cerevisiae.

Authors:  E W Lusby; C S McLaughlin
Journal:  Mol Gen Genet       Date:  1980-04
View more
  3 in total

1.  l-ornithine activates Ca2+ signaling to exert its protective function on human proximal tubular cells.

Authors:  Samuel Shin; Farai C Gombedza; Bidhan C Bandyopadhyay
Journal:  Cell Signal       Date:  2019-11-23       Impact factor: 4.315

Review 2.  Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: new developments relevant to the clinician.

Authors:  Salih Pay; Robert Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

Review 3.  Calcium pyrophosphate crystal deposition disease: diagnosis and treatment.

Authors:  José Luis Rosales-Alexander; Jerónimo Balsalobre Aznar; César Magro-Checa
Journal:  Open Access Rheumatol       Date:  2014-05-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.